upleganan   Click here for help

GtoPdb Ligand ID: 12797

Synonyms: compound 44 [PMID: 31525992] | EVER206 | SPR206
Compound class: Synthetic organic
Comment: Upleganan (SPR206) is a polymyxin antibacterial with activity against multi-drug resistant (MDR) Gram-negative species, together with lower nephrotoxicity than polymyxin B [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 27
Hydrogen bond donors 17
Rotatable bonds 25
Topological polar surface area 461.56
Molecular weight 1144.76
XLogP -1.47
No. Lipinski's rules broken 4
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)C[C@H]1C(=O)N[C@@H](CCN)C(=O)N[C@@H](CCN)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC[C@@H](C(=O)N[C@@H](CCN)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N1)NC(=O)[C@H](CN)NC(=O)[C@H]([C@@H](C)O)NC(=O)C[C@H](CN)C3=CC=CC(=C3)Cl
Isomeric SMILES C([C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCN)C(=O)N[C@@H](CCN)C(=O)N[C@@]([C@@H](C)O)(C(=O)NCC[C@H](NC([C@@H](NC([C@@H](NC(C[C@H](CN)C2=CC(Cl)=CC=C2)=O)[C@@H](C)O)=O)CN)=O)C(=O)N[C@@H](CCN)C(=O)N1)[H])C3=CC=CC=C3
InChI InChI=1S/C52H82ClN15O12/c1-27(2)21-38-48(76)62-34(13-17-54)44(72)61-36(15-19-56)47(75)68-42(28(3)69)51(79)59-20-16-37(46(74)60-35(14-18-55)45(73)65-39(49(77)64-38)22-30-9-6-5-7-10-30)63-50(78)40(26-58)66-52(80)43(29(4)70)67-41(71)24-32(25-57)31-11-8-12-33(53)23-31/h5-12,23,27-29,32,34-40,42-43,69-70H,13-22,24-26,54-58H2,1-4H3,(H,59,79)(H,60,74)(H,61,72)(H,62,76)(H,63,78)(H,64,77)(H,65,73)(H,66,80)(H,67,71)(H,68,75)/t28-,29-,32-,34+,35+,36+,37+,38+,39-,40+,42+,43+/m1/s1
InChI Key VAZVBVUQVUHPMS-DFEDBOKMSA-N
References
1. Brown P, Abbott E, Abdulle O, Boakes S, Coleman S, Divall N, Duperchy E, Moss S, Rivers D, Simonovic M et al.. (2019)
Design of Next Generation Polymyxins with Lower Toxicity: The Discovery of SPR206.
ACS Infect Dis, 5 (10): 1645-1656. [PMID:31525992]
2. Bruss J, Lister T, Gupta VK, Stone E, Morelli L, Lei Y, Melnick D. (2021)
Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Polymyxin Derivative SPR206.
Antimicrob Agents Chemother, 65 (10): e0073921. [PMID:34339267]
3. Rodvold KA, Bader J, Bruss JB, Hamed K. (2023)
Pharmacokinetics of SPR206 in Plasma, Pulmonary Epithelial Lining Fluid, and Alveolar Macrophages following Intravenous Administration to Healthy Adult Subjects.
Antimicrob Agents Chemother, 67 (7): e0042623. [PMID:37338378]
4. Zhang Y, Zhao C, Wang Q, Wang X, Chen H, Li H, Zhang F, Wang H. (2020)
Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli.
J Antimicrob Chemother, 75 (9): 2609-2615. [PMID:32591806]